Uppdatering: I juni/juli 2013 gör Bluefish riktade nyemissioner (till Nexttobe AB, Färna Invest AB och övriga aktieägare) på upp till sammanlagt 50 Mkr. Samtidigt erbjuds innehavare av konvertibla skuldebrev att konvertera till aktier för 60 Mkr, alternativt att förlänga löptiden.

Company profile page for Nexttobe AB including stock price, company news, press releases, executives, board members, and contact information

Alltid uppdaterat. NXT2B is a fully privately owned venture capital company. We are able to make fast decisions on any investment opportunities since we do not require any external capital. Company profile page for Nexttobe AB including stock price, company news, press releases, executives, board members, and contact information NXT2B was started in 2011 by the Swedish entrepreneur Bengt Ågerup and he is now acting as senior adviser to the company. Bengt has held senior positions within Pharmacia and Biomatrix and started the company Q-Med that was subsequently sold to Galderma in 2011. AllgoHolding AB Bioimics AB Bluefish Pharmaceuticals AB Delta Projects AB Hansa Biopharma AB Lokon Pharma AB Lumina Adhesives AB Navinci Diagnostics AB Q-linea AB Repos Pharma AB Scint-X AB Sweden Carnica Group AB Vivolux AB Angelica is the CEO of Lokon Pharma AB and a Professor of Immunotherapy at Uppsala University.

Nexttobe currently holds 5,755,379 shares in Hansa Biopharma, representing approximately 12.5% of the total shares and 12.9% of total votes outstanding in Hansa Biopharma. Assuming all the 3.6 million shares offered in the Share Sale are sold, Nexttobe will hold approximately 2.3 million shares, corresponding to approximately 4.7% of total shares and 4.8% of total votes outstanding in Hansa Biopharma. AllgoHolding AB Bioimics AB Bluefish Pharmaceuticals AB Delta Projects AB Hansa Biopharma AB Lokon Pharma AB Lumina Adhesives AB Navinci Diagnostics AB Q-linea AB Repos Pharma AB Scint-X AB Sweden Carnica Group AB Vivolux AB CEO of Nexttobe AB. Erika has been working in the life science sector for 15 years. Before joining nxt2b she served as CFO of OxThera AB, prior to that as Vice president and CFO of Q-Med AB and as CFO and CEO of BioPhausia AB (publ.). NXT2B was started in 2011 by the Swedish entrepreneur Bengt Ågerup and he is now acting as senior adviser to the company. Bengt has held senior positions within Pharmacia and Biomatrix and started the company Q-Med that was subsequently sold to Galderma in 2011. Angelica is the CEO of Lokon Pharma AB and a Professor of Immunotherapy at Uppsala University.

Kontakta oss. Bluefish Pharmaceuticals AB Gävlegatan 22 SE-113 30 Stockholm, Sweden Tel: +46 8 5191 1600 Fax: +46 8 5191 1690 info-se@bluefishpharma.com

In August 2018, when Nexttobe AB requested the final settlement of Oasmia’s entire debt, it became evident that PA would rather allow Nexttobe to initiate bankruptcy proceedings against Oasmia than to participate in a settlement of Oasmia’s debt to Nexttobe, even though PA had undertaken to fund such a settlement. These changes follow the purchase by Nexttobe AB (nxt2b) of a significant part of the shares in Olink as announced last week, and it is a first step to accelerate the development of Olink. New members of the Board of Directors have also been appointed, and Bengt Ågerup will be the Chairman of the Board.

Nexttobe AB (556624-5717). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar.

Uppsala, Sver 2021-03-23 Nexttobe AB,556624-5717 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för Nexttobe AB Nexttobe AB (556624-5717). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar.

Nexttobe AB - Org.nummer: 5566245717. Vid senaste bokslut 2019 hade företaget en omsättningsförändring på -94,6%. Fördelningen i styrelsen är 33,3 % män (1), 66,7 % kvinnor (2) . Bolagets VD är Erika Kjellberg Eriksson 59 år.
Tidsviktad avkastning

Nexttobe AB är ett ledande riskkapitalbolag som Tagged Nexttobe AB. Home · Nexttobe AB · Nyhetssvepet måndag 2 oktober. 2 oktober, 2017. Ett redaktionellt urval av dagens Life Science-nyheter De senaste Nexttobe AB - Hitta nyheter, ekonomiska siffror, kontaktuppgifter, nyckeltal, bokslut, styrelse, koncernträd och så mycket mer på bizzdo.se. Verksamheter som utövas av huvudkontor. 556624-5717.

Bengt Ågerups investmentbolag Nexttobe har avyttrat hela innehavet i läkemedelsföretaget Realtid Media AB Kjellberg Eriksson som representant för Nexttobe AB, Max Mitteregger som representant för Gladiator och Fredrik Bogren som representant för Uppsala, den 30 maj 2018 --- Oasmia Pharmaceutical AB (NASDAQ: OASM) meddelar idag att Nexttobe AB har förlängt sitt lån till bolaget. I syfte att bredda ägandet i bolaget ges det svenska aktiebolaget Nexttobe AB (NXT2B) rätt att teckna aktierna, i stället för aktieägarna. Oasmia Pharmaceuticals AB:s styrelse har den 17 december i ett ett lån som företaget Nexttobe AB (Nexttobe) lämnat Oasmia redan 2015, Cancel Cancel your follow request to @MF_Holdings.
Om strategier i engelska och moderna språk

skatt golf sportscombi
global trade services
coop färjestaden erbjudande
varbergs - malmo ff
swedbank robur penningmarknadsfond
biltema press release
lidkoping kommun jobb

Nexttobe AB gick med vinst (2019) Nexttobe AB gick med vinst, 1 071 801 000 kr. Nexttobe AB minskade sin omsättning med -94,63% senaste räkenskapsåret. Bolaget har 2 anställda, snittlönen har ökat 1611,68%.

In May, we introduced our newest product candi-date, OAS-19. It is a unique concept, whereby two chemotherapy drugs can now be given in a single infusion due to the properties of XR-17.